Search

Displaying results 1431 - 1440 of 1777 in total
  1. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic

  2. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    Cannabidivarin, also known as cannabidivarol or CBDV, is a non-psychoactive cannabinoid found within DB14009. It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis,...

  3. Drug

    Emricasan

    go.drugbank.com/drugs/DB05408
    Investigational

    Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA.

  4. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  5. Drug

    Melarsomine

    go.drugbank.com/drugs/DB11528
    ExperimentalVet approved

    It is the only FDA-approved treatment for adult heartworm infection in dogs, however, is is not approved for use in dogs with late-stage infection.

  6. Drug

    Denileukin diftitox

    go.drugbank.com/drugs/DB00004
    ApprovedInvestigational

    [A264349, L51254] Denileukin diftitox was originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin

  7. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP.

  8. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    [L42425] Pegloticase was approved by the FDA in 2014, and in 2022, the drug label included the co-administration of pegloticase and methotrexate.[L42425]

  9. Drug

    Avacincaptad pegol

    go.drugbank.com/drugs/DB15165
    ApprovedInvestigational

    [A260801] Avacincaptag pegol was approved by the FDA on August 4, 2023, under the brand name IZERVAY for the treatment of GA secondary to AMD.

  10. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia.